Effector T cells require fatty acid metabolism during murine graft-versus-host disease

CA Byersdorfer, V Tkachev, AW Opipari… - Blood, The Journal …, 2013 - ashpublications.org
CA Byersdorfer, V Tkachev, AW Opipari, S Goodell, J Swanson, S Sandquist, GD Glick
Blood, The Journal of the American Society of Hematology, 2013ashpublications.org
Activated T cells require increased energy to proliferate and mediate effector functions, but
the metabolic changes that occur in T cells following stimulation in vivo are poorly
understood, particularly in the context of inflammation. We have previously shown that T
cells activated during graft-versus-host disease (GVHD) primarily rely on oxidative
phosphorylation to synthesize adenosine 5′-triphosphate. Here, we demonstrate that
alloreactive effector T cells (Teff) use fatty acids (FAs) as a fuel source to support their in vivo …
Abstract
Activated T cells require increased energy to proliferate and mediate effector functions, but the metabolic changes that occur in T cells following stimulation in vivo are poorly understood, particularly in the context of inflammation. We have previously shown that T cells activated during graft-versus-host disease (GVHD) primarily rely on oxidative phosphorylation to synthesize adenosine 5′-triphosphate. Here, we demonstrate that alloreactive effector T cells (Teff) use fatty acids (FAs) as a fuel source to support their in vivo activation. Alloreactive T cells increased FA transport, elevated levels of FA oxidation enzymes, up-regulated transcriptional coactivators to drive oxidative metabolism, and increased their rates of FA oxidation. Importantly, increases in FA transport and up-regulation of FA oxidation machinery occurred specifically in T cells during GVHD and were not seen in Teff following acute activation. Pharmacological blockade of FA oxidation decreased the survival of alloreactive T cells but did not influence the survival of T cells during normal immune reconstitution. These studies suggest that pathways controlling FA metabolism might serve as therapeutic targets to treat GVHD and other T-cell–mediated immune diseases.
ashpublications.org